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Clinical trials play a pivotal role in improving patient outcome in cancer and non-malignant 
disease1,2. Rapid assessment of novel therapies plays a central role in the evaluation of new 
drugs by National Institute for Clinical Excellence (NICE)3. In 2016-17, 670,000 people were 
recruited into more than 4,700 trials across the NHS4 - consequent upon investment of more 
than £200 million annually into the Clinical Research Network of the National Institute for 
Health Research (NIHR)5.  
 
In the UK, cancer trials are developed by the National Cancer Research Institute (NCRI) and 
delivered by the NIHR. This internationally significant trial portfolio includes large phase III 
randomised controlled trials that usually compare the standard of care to new therapies and 
combinations6. The study drugs are often provided free-of-charge to the NHS by 
pharmaceutical companies. In addition to improving clinical outcomes by providing access to 
free drugs, accelerated trial delivery drives economic growth and represents a centrally 
important feature of the UK Life Sciences proposition, as articulated in HM Government’s Life 
Sciences Industrial Strategy7.  
 
Blood cancer represents one of the most significant areas of recent therapeutic advance. 
Thousands of UK patients have benefited from access to often dramatically effective new 
therapies consequent upon clinical trial entry often before their routine commissioning by 
NHS England. In order to quantify this often-unrecognised benefit to the UK health economy 
we have calculated the direct drug savings from three of the largest clinical trials in common 
blood cancers; namely, chronic myeloid leukaemia (SPIRIT-2), chronic lymphocytic leukaemia 
(FLAIR) and multiple myeloma (Myeloma XII) (see Table 1). Non-trial drug costs were based 
on NHS England specialised commissioning pricing.  Taken together these three trials 
provided access to more than £200 million free drug to 1737 trial patients. Consequently, in 
addition to the pivotal importance of these clinical trials in defining improved treatment 
strategies in three of the most important blood cancers they also generated substantial cost 
savings to NHS patients. These economies are amplified by the fact that in addition to 
receiving free drug the costs of standard treatment were not incurred by these patients 
either. Consequently, the cost savings across the whole NCRI trial portfolio is likely to be at 
least an order of magnitude higher than that outlined.  
 
The savings identified in these three trials have been replicated in a range of early phase 
clinical trials in blood cancer delivered by the Trials Acceleration Programme (TAP), flagged 
as a beacon of best practice in the Life Sciences Industrial Strategy. TAP has produced more 
than £100 million of savings to the UK health economy whilst benefitting patients and 
fostering the pharma/NHS relationship. Such initiatives generate substantial value in the form 
of novel intellectual property and by acting as a magnet for inward investment into UK PLC. 
The potential of the NHS to facilitate the acceleration of promising new agents from phase 
I/II trials to larger phase III trials through programmes such as TAP linked to NCRI Phase III 
Trials is huge. The NHS’s unparalleled position to facilitate the transfer from early to late stage 
clinical trials within a single healthcare system should be embraced in order to rapidly 
accumulate evidence and improve outcomes for our patients. All UK patients, when feasible, 
should be offered the opportunity of entry into well designed cutting edge clinical trials. 
 
Patient outcomes are currently being transformed by an unprecedented wave of novel 
therapies. The UK’s inherent strengths in accelerated trial delivery is currently hampered by 
a number of bottlenecks including limitations in funding for clinical trial networks and 
protracted delays in trial set up. In order to continue to attract inward investment from the 
pharmaceutical sector and to enable the rapid assessment of novel therapies, consistent with 
HM Government’s Life Sciences Industrial Strategy, a proportion of the substantial savings we 
have described should be invested into NIHR trials networks. Such investment is urgently 
required in order to deliver a clinical trials infrastructure which is fit for purpose in 2019 so 
that more patients can benefit from therapeutic breakthroughs as rapidly as possible and to 
release the enormous economic benefits of the UK life sciences sector.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Trial Name SPIRIT 2 FLAIR Myeloma XII 
Disease Chronic Myeloid Leukaemia Chronic Lymphocytic Leukaemia Multiple Myeloma 
Number of Patients in 
Trial 
812 1576 406 
Number of patients 
Contributing to Cost 
Saving 
406 925 406 
How costs saved 1:1 randomisation between 
imatinib and dasatinib. Cost saving 
is because patients treated on 
dasatinib would otherwise have 
received commercial imatinib on 
NHS at full price. Saving accrued for 
up to 9 years as free supply of 
dasatinib was for 5 years from 
point of last patient recruited. 
Recruitment took 4 years. 
Comparison of standard of care 
(fludarabine/cyclophosphamide/rit
uximab) vs Ibrutinib + Rituximab, 
Ibrutinib alone and Ibrutinib + 
venetoclax. Free IMPs in the trial 
were Ibrutinib (up to 6 years) and 
venetoclax (up to 6 years) 
Non-randomised upfront 
treatment with 
ixazomib/thalidomide/dexametha
sone. Standard of care is with 
bortezomib/cyclophosmamide/de
xamethasone (6 cycles). 
Randomised to receive addition 
ixazomib with autoSCT and 
consolidation or maintenance. 
Cost saving drug(s) Imatinib Fludarabine/cyclophosphamide/ibr
utinib 
Bortezomib/cyclophosphamide/d
examethasone 
Cost-saving drug (inc 
VAT) per patient/year 
£24,831 £14,814 £3,707 
Total Treatment cost 
savings, based on cost 
modelling 
£66,115,858/£75,238,584 £13,702,950 £1,505,212 
 
‘Free drug’ saving, 
based on cost 
modelling 
n/a Ibrutinib: 
£202,926,276/£357,342,300 
Venetoclax: 
£76,008,034/£120,047,274 
Ixazomib: £25,038,858 
Cost modelling Patient years modelled on 100 
patients accrued per year for 4 
years, 406 patients on study for 
subsequent 5 years. Lower limit 
scenario assumes subsequent 10% 
annual dropout rate; upper limit 
assumes no drop outs. 
Treatment cost saving is 
determined by patients 
randomised to an ibrutinib arm.  
Patient years modelling for 'free 
drug' (i.e. longer duration follow-
up) assumes 6 year 'free drug', with 
upper limits assuming no dropout 
rate and no patients achieving MRD 
and lower limit assuming 10% 
annual dropout rate and a 
cumulative 30% achieving MRD 
negativity over the follow-up 
period (according to data from 
CLARITY). 
Treatment cost saving is 
determined by patients 
randomised to ITD in induction. 
‘Free drug’ determined by trial 
protocol (i.e. 6 cycles induction, 2 
consolidation, and free 
maintenance for 25% of patients). 
Maintenance duration based on 
Tourmaline MM3 clinical trial 
time-to-progression (i.e. 15.2 
months)  
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